Skip to main content

CORRECTION article

Front. Pharmacol., 30 September 2024
Sec. Neuropharmacology
This article is part of the Research Topic 'Pain and pain-related neuropsychiatric disorders: from mechanistic insights to innovative therapeutic strategies.' View all 10 articles

Corrigendum: Long-term efficacy and reduced side-effects of buprenorphine in patients with moderate and severe chronic pain

Alfonso Papa
Alfonso Papa1*Anna Maria SalzanoAnna Maria Salzano1Maria Teresa Di DatoMaria Teresa Di Dato1Vincenzo DesiderioVincenzo Desiderio2Pietro BuonavolontPietro Buonavolontà1Pietro MangoPietro Mango1Elisabetta SaraccoElisabetta Saracco1Dario TammaroDario Tammaro1Livio Luongo&#x;Livio Luongo3Sabatino Maione&#x;Sabatino Maione3
  • 1Department of Pain Management—AO “Ospedale dei Colli”–Monaldi Hospital, Napoli, Italy
  • 2Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
  • 3Department of Experimental Medicine, Division of Pharmacology, University of Campania “Luigi Vanvitelli”, Naples, Italy

A Corrigendum on
Long-term efficacy and reduced side-effects of buprenorphine in patients with moderate and severe chronic pain

by Papa A, Salzano AM, Di Dato MT, Desiderio V, Buonavolontà P, Mango P, Saracco E, Tammaro D, Luongo L and Maione S (2024). Front. Pharmacol. 15:1454601. doi: 10.3389/fphar.2024.1454601

In the published article, there was an error in Figures 1, 4, 5 as published. The figures were mismatched with their respective images.

Figure 1 should display the image originally intended for Figure 5; the caption remains correct. The corrected Figure 1 and its caption appear below.

Figure 1
www.frontiersin.org

Figure 1. Additional therapies prescribed alongside buprenorphine for chronic pain management. Among the 248 patients enrolled, 118 with severe pain and 34 with moderate pain were prescribed adjuvant treatments, including anticonvulsants, topical agents, antidepressants, sedatives, and NSAIDs/corticosteroids.

Figure 4 should display the image originally intended for Figure 1; the caption remains correct. The corrected Figure 4 and its caption appear below.

Figure 4
www.frontiersin.org

Figure 4. Patient-reported outcomes assessed by PGIC. The figure shows the results of the Patients’ Global Impression of Change (PGIC) scale, specifically designed to assess patients’ perceptions of change following treatment. This seven-point verbal scale offers options ranging from “very much improved” to “very much worsened,” including “much improved,” “minimally improved,” “no change,” “minimally worsened,” and “much worsened.” indicating high levels of patient satisfaction and perceived improvement in pain management across different pain intensities.

Figure 5 should display the image originally intended for Figure 4; the caption remains correct. The corrected Figure 5 and its caption appear below.

Figure 5
www.frontiersin.org

Figure 5. Trends in morphine-equivalent doses for moderate pain patients. This graph illustrates the morphine-equivalent doses, calculated from buprenorphine dosages over 36 months for patients with moderate pain, using an equianalgesic conversion factor, where 5 μg per hour of transdermal buprenorphine equates to 12 mg of morphine per day. The doses at each time point (baseline, 6, 12, 24, and 36 months) are plotted to assess any increase that might indicate opioid tolerance. The graph displays both the actual recorded doses until 36 months (black dots) and the projected morphine-equivalent doses (blue triangles) up to 72 months, in patients with moderate pain. The red dashed line indicates the opioid tolerance threshold of 60 mg/day, as defined by FDA. Linear regression analysis was employed to determine the slope of the dose trend, represented as mg/month, which quantifies the rate of increase in dosage requirements. The slope of 0.4117 mg/month suggests a very gradual increase in required dosage, remaining significantly below the 60 mg/day threshold associated with opioid tolerance, even at a projected period of 72 months.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: chronic pain, opioids, tolerance, ransdermal patches, pain relief, opioid crisis

Citation: Papa A, Salzano AM, Di Dato MT, Desiderio V, Buonavolontà P, Mango P, Saracco E, Tammaro D, Luongo L and Maione S (2024) Corrigendum: Long-term efficacy and reduced side-effects of buprenorphine in patients with moderate and severe chronic pain. Front. Pharmacol. 15:1491886. doi: 10.3389/fphar.2024.1491886

Received: 05 September 2024; Accepted: 10 September 2024;
Published: 30 September 2024.

Edited and reviewed by:

Álvaro Llorente-Berzal, Autonomous University of Madrid, Spain

Copyright © 2024 Papa, Salzano, Di Dato, Desiderio, Buonavolontà, Mango, Saracco, Tammaro, Luongo and Maione. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Alfonso Papa, alfonsopapa@libero.it

These authors have contributed equally to this work and share last authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.